Dermata Therapeuticsinc Nasdaqdrmais A Clinical Stage Biotechnology Company Focusing On The Treatment Of Medical And Aesthetic Skin Conditionsthe Company S Lead Product Candidatedmt310Is The First Product Candidate Being Developed From Its Spongilla Technology Platformdmt310 Is A Once Weekly Topical Product Candidate Derived From A Naturally Sourced Freshwater Sponge With Multiple Unique Mechanisms Of Actiondmt310 Is Currently Under Clinical Development For The Treatment Of Acnepsoriasisand Rosaceaour Second Product Candidatedmt410Uses Our Spongilla Technology As A New Method For Topical Intradermal Delivery Of Botulinum Toxin For The Treatment Of Multiple Aesthetic Skin Conditionsdermata Is Headquartered In San Diegocaliforniafor More Informationplease Visit Http Www Dermatarx Com
